European experience on the practical use of levosimendan in patients with acute heart failure syndromes

Detalhes bibliográficos
Autor(a) principal: Follath, F
Data de Publicação: 2005
Outros Autores: Franco, F, Cardoso, JS
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
Texto Completo: http://hdl.handle.net/10400.4/508
Resumo: The novel calcium sensitizer and ATP-dependent potassium channel opener levosimendan has been introduced for routine use in several European countries. Recent reports on clinical experience confirm the positive hemodynamic results and beneficial clinical effects described in the initial dose-finding and randomized comparative therapeutic trials in patients with severe low-output heart failure. In addition, studies in small series of patients with cardiogenic shock after myocardial infarction and/or surgical interventions and post-interventional myocardial dysfunction (stunning) indicate that the inotropic and vasodilating actions of levosimendan may be of value in a wider range of indications. Dose recommendations, combination with other drugs, and potential side effects are discussed in this overview.
id RCAP_a3fedbe29ea7162922d5ed71d23bc84d
oai_identifier_str oai:rihuc.huc.min-saude.pt:10400.4/508
network_acronym_str RCAP
network_name_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository_id_str https://opendoar.ac.uk/repository/7160
spelling European experience on the practical use of levosimendan in patients with acute heart failure syndromesInsuficiência CardíacaHidrazonasPiridazinaCardiotónicosEuropaThe novel calcium sensitizer and ATP-dependent potassium channel opener levosimendan has been introduced for routine use in several European countries. Recent reports on clinical experience confirm the positive hemodynamic results and beneficial clinical effects described in the initial dose-finding and randomized comparative therapeutic trials in patients with severe low-output heart failure. In addition, studies in small series of patients with cardiogenic shock after myocardial infarction and/or surgical interventions and post-interventional myocardial dysfunction (stunning) indicate that the inotropic and vasodilating actions of levosimendan may be of value in a wider range of indications. Dose recommendations, combination with other drugs, and potential side effects are discussed in this overview.ElsevierRIHUCFollath, FFranco, FCardoso, JS2009-05-21T09:48:35Z20052005-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.4/508enginfo:eu-repo/semantics/openAccessreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAP2025-01-30T03:20:22Zoai:rihuc.huc.min-saude.pt:10400.4/508Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-28T19:43:19.756373Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse
dc.title.none.fl_str_mv European experience on the practical use of levosimendan in patients with acute heart failure syndromes
title European experience on the practical use of levosimendan in patients with acute heart failure syndromes
spellingShingle European experience on the practical use of levosimendan in patients with acute heart failure syndromes
Follath, F
Insuficiência Cardíaca
Hidrazonas
Piridazina
Cardiotónicos
Europa
title_short European experience on the practical use of levosimendan in patients with acute heart failure syndromes
title_full European experience on the practical use of levosimendan in patients with acute heart failure syndromes
title_fullStr European experience on the practical use of levosimendan in patients with acute heart failure syndromes
title_full_unstemmed European experience on the practical use of levosimendan in patients with acute heart failure syndromes
title_sort European experience on the practical use of levosimendan in patients with acute heart failure syndromes
author Follath, F
author_facet Follath, F
Franco, F
Cardoso, JS
author_role author
author2 Franco, F
Cardoso, JS
author2_role author
author
dc.contributor.none.fl_str_mv RIHUC
dc.contributor.author.fl_str_mv Follath, F
Franco, F
Cardoso, JS
dc.subject.por.fl_str_mv Insuficiência Cardíaca
Hidrazonas
Piridazina
Cardiotónicos
Europa
topic Insuficiência Cardíaca
Hidrazonas
Piridazina
Cardiotónicos
Europa
description The novel calcium sensitizer and ATP-dependent potassium channel opener levosimendan has been introduced for routine use in several European countries. Recent reports on clinical experience confirm the positive hemodynamic results and beneficial clinical effects described in the initial dose-finding and randomized comparative therapeutic trials in patients with severe low-output heart failure. In addition, studies in small series of patients with cardiogenic shock after myocardial infarction and/or surgical interventions and post-interventional myocardial dysfunction (stunning) indicate that the inotropic and vasodilating actions of levosimendan may be of value in a wider range of indications. Dose recommendations, combination with other drugs, and potential side effects are discussed in this overview.
publishDate 2005
dc.date.none.fl_str_mv 2005
2005-01-01T00:00:00Z
2009-05-21T09:48:35Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.4/508
url http://hdl.handle.net/10400.4/508
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron:RCAAP
instname_str FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron_str RCAAP
institution RCAAP
reponame_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
collection Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository.name.fl_str_mv Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
repository.mail.fl_str_mv info@rcaap.pt
_version_ 1833598283451203585

Registros relacionados